S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Henry Ford Would NEVER Have Seen This Coming (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
Henry Ford Would NEVER Have Seen This Coming (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company

NovoCure Stock Price, News & Analysis (NASDAQ:NVCR)

$12.77
-0.22 (-1.69%)
(As of 12/5/2023 ET)
Compare
Today's Range
$12.48
$12.90
50-Day Range
$11.13
$17.00
52-Week Range
$10.87
$120.03
Volume
1.46 million shs
Average Volume
1.39 million shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.29

NovoCure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
254.6% Upside
$45.29 Price Target
Short Interest
Healthy
8.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
-0.08mentions of NovoCure in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$4,832 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.04) to ($1.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

382nd out of 948 stocks

Medical Devices Industry

8th out of 17 stocks


NVCR stock logo

About NovoCure Stock (NASDAQ:NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Stock Price History

NVCR Stock News Headlines

Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Novocure to Cut 13% of Workforce in Restructuring
Novocure To Reduce 13% Of Current Workforce - Quick Facts
NovoCure: Significant Upside Even Without A Breakthrough
Is Novocure Stock a Buy?
The NovoCure Ltd (NVCR) Company: A Short SWOT Analysis
H.C. Wainwright Reaffirms Their Hold Rating on NovoCure (NVCR)
Why Novocure Stock Was Sick Today
NovoCure Ltd (NVCR) Reports Q3 2023 Financial Results
NovoCure (NVCR) Q3 2023 Earnings Call Transcript
Novocure Reports Third Quarter 2023 Financial Results
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,320
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.29
High Stock Price Target
$51.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+254.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-92,530,000.00
Pretax Margin
-36.86%

Debt

Sales & Book Value

Annual Sales
$537.84 million
Book Value
$4.20 per share

Miscellaneous

Free Float
100,802,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
0.52
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report














NVCR Stock Analysis - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price target for 2024?

8 brokerages have issued 12-month target prices for NovoCure's shares. Their NVCR share price targets range from $25.00 to $51.00. On average, they anticipate the company's stock price to reach $45.29 in the next year. This suggests a possible upside of 254.6% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2023?

NovoCure's stock was trading at $73.35 on January 1st, 2023. Since then, NVCR shares have decreased by 82.6% and is now trading at $12.77.
View the best growth stocks for 2023 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.05. The medical equipment provider had revenue of $127.30 million for the quarter, compared to analysts' expectations of $128.75 million. NovoCure had a negative net margin of 39.14% and a negative trailing twelve-month return on equity of 46.89%. NovoCure's quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) EPS.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Baillie Gifford & Co. (6.38%), Morgan Stanley (1.02%), Palo Alto Investors LP (0.62%), Charles Schwab Investment Management Inc. (0.51%) and Northern Trust Corp (0.41%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NVCR) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -